The investment firm initiated coverage of the biopharma stock at a outperform rating.
Get this delivered to your inbox, and more info about our products and services.
BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says.
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
The investment bank upgraded the pharma stock to overweight from equal weight.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
HSBC signals a potential cooling period for the red-hot obesity drug trade.
The investment bank upgraded the pharmaceutical name to buy from neutral.
